Emyria Limited (ASX:EMD)

Market Cap	46.78M +198.7%
Revenue (ttm)	1.39M -36.7%
Net Income	-3.14M
EPS	-0.01
Shares Out	806.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	656,382
Average Volume	1,678,961
Open	0.0560
Previous Close	0.0580
Day's Range	0.0550 - 0.0570
52-Week Range	0.0210 - 0.0780
Beta	0.06
RSI	52.72
Earnings Date	Feb 2, 2026

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnersh...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In fiscal year 2025, Emyria's revenue was 1.39 million, a decrease of -36.68% compared to the previous year's 2.20 million. Losses were -3.14 million, -72.57% less than in 2024.